Report Company Directory

Aslan Pharmaceuticals

• ASLAN Pharmaceuticals to Present at the Annual Needham Virtual Healthcare Conference 2022 by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Late-Breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting by GlobeNewsWire
• ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting by GlobeNewsWire
• ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer by GlobeNewsWire
• ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis by GlobeNewsWire
• ASLAN Pharmaceuticals to Host New Episode in A4 KOL Series: Aspects of Atopic Dermatitis and ASLAN004 by GlobeNewsWire
• ASLAN Pharmaceuticals to Present Additional Data From Aslan004 Proof-Of-Concept Study at Two Upcoming Winter Dermatology Conferences by GlobeNewsWire
• ASLAN Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference by GlobeNewsWire

Aslan Pharmaceuticals ADS

• ASLAN Pharmaceuticals Announces it Has Filed for Voluntary Liquidation of Its Sole Operating Subsidiary and is Commencing Steps to Place Itself Into Voluntary Liquidation by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Receipt of Nasdaq Delisting Determination; Has Determined Not to Appeal by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change by GlobeNewsWire
• ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference by GlobeNewsWire
• ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update by GlobeNewsWire
• ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics by GlobeNewsWire
• ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference by GlobeNewsWire
• ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients by GlobeNewsWire

ASM AUTOMATION GROUP BERHAD

ASM Group SA

• Ford Equity International Rating and Forecast Report by Ford Equity Research

ASM International N.V.

• What returns to expect on Cloud AI? by New Street Research
• Capex revisions, Replatforming, Memory Pricing, Semicap, Tesla, Apple. Tech weekly wrap-up by New Street Research
• Absolutely Fabulous 2026 - Tracking EUV Capacity by BNP Paribas
• UBS: Fast Take: HOLT TMT "ASML shares hit record high as Q4 net bookings..." by UBS AG
• ING Benelux Favourites/Aedifica, Ageas, ASM International, Basic-Fit, D'Ieteren, Lotus Bakeries, SBM Offshore, Theon International, Vopak and Wolters Kluwer by ING Financial Markets
• CQ4’25 Previews by BNP Paribas
• BE Semiconductor Industries "Structural 2026 tailwinds - bond voyage" (Buy) by UBS AG
• 2026 European Conviction Stock Ideas "Identifying our best ideas" Neumann by UBS AG
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 22/01/2026 by Oddo BHF
• ODDO BHF SECURITIES Small & MIDCAP MORNING NEWS – 01/22/2026 by Oddo BHF